Three series of 2,3-dihydroquinazolin-4(1H)-one derivatives were prepared. Most of the compounds had significant fXa inhibitory activity. 8e exhibited the strongest potency against fXa and good selectivity versus thrombin. 8e also displayed great in vitro and in vivo antithrombotic activity. 8e had a similar safety profile on bleeding risk as that of betrixaban.